MedTrace Logo

Extended Follow-Up After Islet Transplantation in T1D

NCT01369082 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2017-11-09

No results posted yet for this study

Summary

The purpose of this study is to provide patients who have received at least one islet transplant as a previous participant in a Clinical Islet Transplantation Consortium (CIT) clinical trial with maintenance immunosuppressive medications and to collect information about the safety of the medications and islet function.

Conditions

  • Type 1 Diabetes (T1D)
  • Islet Transplantation

Interventions

DRUG

Maintenance Immunosuppressive Treatment

All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Clinical Islet Transplantation Consortium

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Bernhard Hering, MD · University of Minnesota

  • Ali Naji, PhD · University of Pennsylvania

  • Camillo Ricordi, MD · University of Miami

  • Andrew Posselt, MD, PhD · University of California, San Francisco

  • Nicole Turgeon, MD · Emory University

  • Xunrong Luo, MD, PhD · Northwestern University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01369082 on ClinicalTrials.gov